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Abstract: Some unverified reports around the world demonstrated that Purslane has therapeutic effects on some 
conditions. The aim of this study was to compare the effects of Purslane and Lovastatin therapy in decreasing 
ƐĞƌƵŵůŝƉŝĚƐ͕ůŝƉŽƉƌŽƚĞŝŶƐ͕ĂŶĚƉĂƌĂŽǆĂŶĂƐĞϭ;WKEϭͿĂĐƟǀŝƚǇ͘ /ŶƚŚŝƐĐůŝŶŝĐĂůƚƌŝĂůƐƚƵĚǇ͕ϵϯƉĂƟĞŶƚƐǁŝƚŚ>>-C more 
than 120 mg/dl who referred to the internal clinic of Kashani hospital in Sahrekord, Iran were selected and divided 
ŝŶƚŽƚǁŽŐƌŽƵƉƐ͗WƵƌƐůĂŶĞ;ϰϮƉĂƟĞŶƚƐͿĂŶĚ>ŽǀĂƐƚĂƟŶ;ϱϭƉĂƟĞŶƚƐͿ͘&ĂƐƟŶŐǀĞŶŽƵƐďůŽŽĚƐĂŵƉůĞƐŽďƚĂŝŶĞĚďĞĨŽƌĞ
ĂŶĚϰϱĚĂǇƐĂŌĞƌƚĂŬŝng Purslane or Lovastatin, levels of all variables in the samples were measured. Our results 
showed that after receiving Purslane or Lovastatin serum level of cholesterol, LDL-C and OxLDL decreased. PON1 
ĂĐƟǀŝƚǇ͕ƉŽϭĂŶĚ,>-C increased but Triglyceride and body mass index (BMI) decreased Only in Purslane group. 
ApoB decreased only after taking Lovastatin. In conclusion, Purslane reduces some cardiovascular risk factors and 
ŝŶĐƌĞĂƐĞƐWKEϭĂĐƟǀŝƟĞƐďĞƩĞƌƚŚĂŶ>ŽǀĂƐƚĂƟŶ͘ 
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1. Introduction 
Portulaca oleracea L. (Common Purslane, 
also known as Khurfeh in Iran) grows in most parts 
of the world and cultures in most countries. There are 
Water, pectin, protein, Carbohydrates, fatty acids, 
particularly unsaturated fatty acid ù3, antioxidant 
substances and Several mineral elements, including: 
iron, copper, manganese, potassium, calcium and 
phosphorus in different parts of this plant (Mohamed 
and Hussein, 1994). 
This plant is an edible succulent weed 
which is widely distributed in Iran. Fresh Purslane 
has a slightly sour and salty taste and is eaten by most 
of the southern aborigines of Iran. It is used as salad 
or is cooked and used as a soup. Its leaves, stems, 
flowers, and seeds are all used in Iranian folk 
medicine. Some unverified reports around the world 
demonstrated that Purslane has therapeutic effects in 
some conditions (Oh et al., 2000). Purslane has been 
traditionally used for treatment against parasites, and 
digestive disorders. It is also used to treat infections 
or bleeding of the genito-urinary tract. The fresh one 
may also be applied topically to relieve sore and 
insect or snakebite (Bensky, 2004). 
Purslane contains many biologically active 
compounds and nutrients, including phenolic alkaloid 
pigments (Yang et al., 2009), flavonoids, glutathione 
and alpha-tocopherol (Simopoulos et al., 1992).  
Reddish Betacyanins and yellow Betaxanthins are 
also found in Purslane (Wang and Yang, 2010). Most 
of these compounds are very potent antioxidants and 
have been found to have anti mutagenic, anti-
inflammatory and anti-fungal activities in laboratory 
studies (Xu et al., 2006). 
Purslane contains more Omega-3 fatty acids 
than any other leafy vegetable plants and it contains 
extraordinary amounts of eicosapentaenoci acid 
(EPA). The leaves of Fresh Purslane are rich in 
alpha-Linolenic acid (Wang and Yang, 2010). It also 
contains polyphenols, vitamins (A,B,C,and 
carotenoids) as well as dietary minerals, such as 
calcium, iron, potassium , magnesium and selenium 
(Barbosa-Filho et al., 2008).  
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Cardiovascular risk factors can reduce by 
these antioxidants, Omega-3 fatty acids and some of 
vitamins or minerals. 
It has been proposed that oxLDL plays an 
important role in the development of therosclerosis 
and is well recognized that HDL plays a protective 
role against atherogenesis and coronary heart disease 
(.QRIODFKHWDO9HNLFHWDO7). HDL has 
also been a carrier of enzymes that destroys the lipid 
hydroperoxides that oxidize LDL phospholipids. 
Human paraoxonase-1 (PON1) is a calcium-
dependent esterase associated with HDL particles 
(Vekic et al., 2007) and the antioxidant activity of 
HDL is largely due to the activity of PON1. Previous 
studies indicated that PON1 plays a protective role 
against the oxidative modification of plasma 
lipoproteins and has been shown to hydrolyze lipid 
peroxides in human atherosclerotic lesions (Fortunato 
et al., 2003). 
The aim of this study was to compare the 
effects of Purslane and Lovastatin therapy in 
decreasing serum lipids, ApoA1 and ApoB 
containing lipoproteins, oxLDL level and PON1 
activity in the two groups of patients with 
hypercholesterolemia from Iran. 
 
2. Material and Methods  
In this clinical trial study, 93 patients with 
LDL-C over than 120 mg/dl who referred to the 
internal clinic of Kashani hospital in Sahrekord, Iran 
were enrolled.   
None of the patients was taking lipid-
lowering drugs or any other medication known to 
affect lipid metabolism before beginning the study. 
The individuals with hypertension, diabetes mellitus, 
thyroid, hepatic, renal diseases and smokers were 
excluded from the study.  
The patients filled out a consent form in and 
the Ethics Committee of the Shahre-kord University 
of Medical Sciences approved the study. The patients 
were divided in two groups of Purslane (N=42) and 
Lovastatin(N=51).  In the Purslane group, almost 50 
gr/day of fresh leaves and stems of Purslane were 
added to the patient's diet for 45 days. The second 
group received 20mg/day Lovastatin for the same 
period.  
The study was approved by the Medical 
plants research center of Shahrekord University of 
Medical Science and its Ethics Committee. All 
patients gave their written informed consent. A 
consent form was read to them carefully and it was 
explained so that it will be fully comprehended and 
lastly signed by them. This study was registered in 
the Iranian  
Registry of Clinical Trials (www.irct.ir) 
with registration number ID: IRCT138902063806N1. 
 
Biochemical analysis: 
A fasting blood sample was obtained from 
the patients before onset of receiving Purslane and 
Lovastatin and the second one, 45 days after the end 
of the treatment. Glucose, total cholesterol (TC) and 
triglycerides (TG) were assayed using standard 
enzymatic procedures. HDL-C and LDL-C were 
measured with direct method and ApoA1 and ApoB 
levels were measured by immunoturbidimeteric 
method. Creatinine also was measured by Jaffe 
method for excluding renal patients. All biochemical 
tests were measured in serum (BT 3000 automatic 
analyzer) using commercial kits by Pars Azmon Co. 
(Iran). Arylesterase activity was measured using 
phenylacetate as the substrate by the modified 
procedure of Kitchen et al (Kitchen et al., 1973).  
PON1 activity toward paraoxon was measured after 
the reaction of paraoxon hydrolysis into p-
nitrophenol and diethylphosphate catalyzed by the 
enzyme (Rainwater et al., 2005). The oxLDL was 
measured by a sandwich ELISA method using a 
commercial kit (Mercodia- Sweden). 
Data were analyzed using independent t-test, 
paired Student t-test and SPSS statistical software 
(ver.=11.5). P value was considered significant 
P<0.05.  
 
3. Results  
The patients fulfilled the process of the 
study and there were no dropouts. The average age of 
the patients in Purslane group was 44±9.6 and the 
Lovastatin group was 49±11.6 years old. No 
significant differences were found between the two 
groups tested in terms of the mean age and gender 
The average Body mass index (BMI) before 
intervention in Purslane and Lovastatin groups were 
27±3.9 and 26±4.9 Kg/m2 respectively (p>0.05). 
There was a significant decrease in serum 
cholesterol, LDL-C and oxLDL in the two groups 
after taking both Purslane and Lovastatin but ApoB 
was decreased only after taking Lovastatin. PON1 
activity was increased in the two groups and PON1 
arylesterase activity, HDL-C and Apo A1only were 
increased in the Purslane group, but BMI and 
triglycerides were decreased in Purslane group (Table 
1).   
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Table 1: The variables measured before and after receiving Purslane and Lovastatin in the patients studied 
            Groups  
Variable 
Purslane (N=42)  Lovastatin (N=51) 
Before 
Mean ±SD 
After  
Mean ±SD 
P value Before  
Mean ±SD 
After  
Mean ±SD 
P value 
BMI (kg/m2) 
FBS (mg/dl) 
Total cholesterol (mg/dl) 
Triglycerides (mg/dl) 
HDL-C (mg/dl) 
LDL-C (mg/dl) 
ApoA1 (mg/dl) 
ApoB (mg/dl) 
OxLDL (U/L) 
PON1 arylesterase activity (U/L) 
PON1 paraxonase activity (U/L) 
27±3.9 
79±17.5 
215±34.5 
189±75.5 
38±10.5 
139±23.3 
125±10.6 
111±18.1 
68±19.1 
95±42.5 
198±111 
25±4.1 
81±19.1 
197±31.6 
169±61.6 
42±10.2 
121±27.5 
131±10.5 
106±19.2 
61±19.9 
114±53.7 
276±132 
0.032 
0.34 
0.02 
0. 01 
0.024 
0.02 
0.03 
0.265 
0.011 
0.012 
0.034 
26±4.2 
88±12.6 
235±29.4 
189±60.7 
39±8.9 
149±28.9 
123±21.9 
125±29.6 
86±14.6 
101±35.6 
205±117 
26±4.4 
86±13.5 
191±31.5 
180±63.6 
41±9.5 
99±31.8 
125±29.5 
98±25.4 
73±15.4 
108±42.1 
265±114 
0.65 
0.19 
0.01 
0.45 
0.38 
0.006 
0.56 
0.004 
0.007 
0.09 
0.021 
 
4. Discussions  
Many studies strongly support the 
hypothesis that oxidative modification of LDL plays 
a crucial role in the pathogenesis of atherosclerosis 
(Berliner JA, Heinecke W, 1996). PON1 may be a 
major defense barrier against lipid peroxides from 
oxidized LDL (Mackness et al., 1993). It needs to be 
known that whether factors, such as diet, medical 
herbs or lipid lowering compounds influence plasma 
PON1 activity or concentration.  
Aryl esterase activity has a direct correlation 
with mass of PON1 protein (Van et al., 2006) and 
serum paraoxanase activity seems to have inverse 
relationship with coronary heart disease (Mackness et 
al., 2003). 
Based on our results, the reduction in serum 
total cholesterol, LDL, oxLDL, and ApoB was 
observed in Lovastatin group which is in agreement 
with several other reports (Clauss et al., 2006). 
Purslane contains almost all of the nutrients 
and it is an excellent source of the antioxidant, 
vitamins, á-tocopherol, â-carotene, and L-
norepinephrine (hanson et al., 2004). 
Triglycerides, total cholesterol, LDL and 
oxLDL were decreased in the group received 
Purslane. Cholesterol reduction is occurring 
principally in LDL-C fraction but HDL-C fraction 
was increased which would be beneficial for reducing 
the risk of cardiovascular disease.  
Purslane is a rich source of Omega 3 fatty 
acids and it has been reported that Omega 3 fatty 
acids reduce LDL-C (Chang et al., 2009).  
High concentrations of Melatonin, a free 
radical scavenger, are recently identified in Purslane 
(6LPRSRXORV HW DO  5RGULJXH] HW DO ). 
Melatonin also reduces LDL-C in rats with high 
cholesterol diet.  Therefore, LDL-C reduction seen in 
our study might be due to Melatonin.  
The presence of other active compounds 
such as alpha-tocopherol, beta-carotene and 
glutathione in Purslane also may play a role in the 
observed hypocholestrolemic effects (Hoyos et al., 
/LXHWal., 2000).  
Following taking of Purslane OxLDL 
decreased. Antioxidant compounds in Purslane 
probably prevents the generation of lipoperoxides 
during the process of LDL oxidation. Purslane herb 
aqueous extracts can prevent oxidant-induced stress 
in the aging mice. The contents of malondialdehyde 
(MDA) were decreased and the activity of superoxide 
dismutase (SOD) was increased in the brain and liver 
of the tested mice (Hongxing et al., 2007). 
Superoxide anion, nitric oxide and hydroxyl radicals 
could be significantly scavenged by Purslane 
polysaccharides (YouGuo et al., 2009). Therefore, 
LDL could be protected from oxidation by Purslane 
polysaccharides which is led to decrease level of 
oxLDL.  
This study also showed that Purslane 
reduces oxLDL level via increasing of paroxonase 
activity. PON1 activity can be modified by factors 
such as diet and lifestyle (Mackness et al., 2002). 
PON1 gene expression has been shown to be affected 
in vitro and in vivo by statins (Suehiro et al., 2000) 
which is consisted with Lovastatin effects in this 
study. 
Purslane is a rich source of polyphenols. 
Polyphenols have antioxidant activity and also, 
modulates gene expression of PON1 leading to 
increased PON1 activity (Suehiro et al., 2000). 
Therefore, the increased PON1 activity was shown in 
our study could be due to Polyphenol contained in 
Purslane. 
 Oleic acid in olive oil is associated with 
increased PON1 activity (Ferretti et al., 2001). PON1 
also was found to be inactivated by oxidized lipids 
and oxidized LDL (Rantala et al., 2002). It has been 
shown that anti-oxidant vitamins such as C and E 
may influence the PON1 activity (Van ET AL., 
2005). 
Life Science Journal 2012;9(4)                                                          http://www.lifesciencesite.com 
 
http://www.lifesciencesite.com             lifesciencej@gmail.com  5551
Purslane has plenty of antioxidant vitamins 
and similar to olive oil is rich of oleic acid and alpha-
linolenic acid (Simopoulos et al., 1992) and thus 
could increase PON1 activity. 
The minor decrease of ApoB density among 
Purslane consumers is may be because of the fact that 
Purslane components less often action the liver 
receptors of lot eliminator. In other word the effect of 
Purslane on the LDL-C ingredient is may be due to 
colestral discharging in gradients not because of lotal 
eliminating by Purslane receptors. So ApoB density 
changed a little.  
Purslane could reduce some well-known 
cardiovascular risk factors such as cholesterol, 
triglyceride, LDL-C and particularly ox LDL. 
Reduction of ox LDL level is result of increasing 
paraoxanase 1 protein concentration and this enzyme 
activity.  
 
Acknowledgements:   
The study was approved by the Medical 
plants research center of Shahrekord University of 
Medical Science and its Ethics Committee. All 
patients gave their written informed consent. A 
consent form was read to them carefully and it was 
explained so that it will be fully comprehended and 
lastly signed by them. This study was registered in 
the Iranian Registry of Clinical Trials (www.irct.ir) 
with registration number ID: IRCT138902063806N1.  
Authors would like to thank the research deputy 
Shahrekord University of Medical Sciences for their 
financial support. 
 
Corresponding Author:  
Assistant professor, Biochemistry research center, 
Shahrekord University of Medical Science, 
Shahrekord, Iran.   
E-mail: kgsamani@yahoo.com 
 
References 
1. Mohamed AI, Hussein AS: Chemical 
composition of purslane (Portulaca oleracea). 
Plant Foods Hum Nutr 1994-9. 
2. Oh KB, Chang IM, Hwang KJ, Mar W: 
Detection of antifungal activity in Portulaca 
oleracea by a single-cell bioassay system. 
Phytother Res 2000-32. 
3. Bensky D: Chinese herbal medicine: materia 
PHGLFD6HDWWOH(DVWODQG3UHVV 
4. Yang Z, Liu C, Xiang L, Zheng Y: Phenolic 
alkaloids as a new class of antioxidants in 
Portulaca oleracea. Phytother Res 2009; 
23:1032-1035. 
5. Simopoulos AP, Norman HA, Gillaspy JE, Duke 
JA: Common purslane: a source of omega-3 fatty 
acids and antioxidants. J Am Coll Nutr 1992; 
11:374-382. 
6. Wang CQ, Yang GQ: Betacyanins from 
Portulaca oleracea L. ameliorate cognition 
deficits and attenuate oxidative damage induced 
by D-galactose in the brains of senescent mice. 
Phytomedicine 2010-532.  
7. Xu X, Yu L, Chen G: Determination of 
flavonoids in Portulaca oleracea L. by capillary 
electrophoresis with electrochemical detection. J 
Pharm Biomed Anal 2006-499.  
8. Barbosa-Filho JM, Alencar AA, Nunes XP, 
Tomaz AC, Sena-Filho JG, Athayde-Filho PF, et 
al: Sources of alpha-, beta-, gamma-, delta- and 
epsilon-carotenes: a twentieth century review.  
Rev Bras Farmacogn 2008-154.  
9. Knoflach M, Kiechl S, Penz D, Zangerle A, 
Schmidauer C, Rossmann A, et al: 
Cardiovascular risk factors and atherosclerosis in 
young women: atherosclerosis risk factors in 
female youngsters (ARFY study). Stroke 2009; 
40:1063-1069. 
10. Gupta N, Gill K, Singh S: Paraoxonases: 
structure, gene polymorphism & role in coronary 
artery disease. Indian J Med Res 2009-
368. 
11. Vekic J, Kotur-Stevuljevic J, Jelic-Ivanovic Z, 
Spasic S, Spasojevic-Kalimanovska V, Topic A, 
et al: Association of oxidative stress and PON1 
with LDL and HDL particle size in middle-aged 
subjects. Eur J Clin Invest 2007-723. 
12. Fortunato G, Rubba P, Panico S, Trono D, Tinto 
N, Mazzaccara C, et al: A paraoxonase gene 
polymorphism, PON 1 (55), as an independent 
risk factor for increased carotid intima-media 
thickness in middle-aged women. 
Atherosclerosis 2003-148. 
13. Kitchen BJ, Masters CJ, Winzor DJ: Effects of 
lipid removal on the molecular size and kinetic 
properties of bovine plasma arylesterase. 
Biochem J 1973-99. 
14. Rainwater DL, Mahaney MC, Wang XL, Rogers 
J, Cox LA, Vandeberg JL: Determinants of 
variation in serum paraoxonase enzyme activity 
in baboons. J Lipid Res 2005-1456.  
15. Berliner JA, Heinecke JW: The role of oxidized 
lipoproteins in atherogenesis. Free Radic Biol 
Med 1996-727. 
16. Mackness MI, Arrol S, Abbott C, Durrington 
PN: Protection of low-density lipoprotein against 
oxidative modification by high-density 
lipoprotein associated paraoxonase. 
$WKHURVFOHURVLV 104:129-135. 
17. Van Himbergen TM, van Tits LJ, Roest M, 
Stalenhoef AF: The story of PON1: how an 
organophosphate-hydrolysing enzyme is 
Life Science Journal 2012;9(4)                                                          http://www.lifesciencesite.com 
 
http://www.lifesciencesite.com             lifesciencej@gmail.com  5552
becoming a player in cardiovascular medicine. 
Neth J Med 2006-38. 
18. Mackness B, Durrington P, McElduff P, Yarnell 
J, Azam N, Watt M, et al: Low paraoxonase 
activity predicts coronary events in the 
Caerphilly Prospective Study. Circulation 2003; 
107: 2775- 2779.  
19. Clauss SB, Holmes KW, Hopkins P, Stein E, 
Cho M, Tate A, et al: Efficacy and safety of 
lovastatin therapy in adolescent girls with 
heterozygous familial hypercholesterolemia. 
Pediatrics 2005-688. 
20. hanson G: Common Purslane. Portulaca 
oleracea.  Idaho: University of Idaho 2004 [cited 
  IHEUXDU\@ $YDLODEOH IURP
<http://pep.wsu.edu/hortsense/scripts/query/displ
ayWeed.asp?problemID=2014&tableName=Wee
d> 
21. Chang CL, Seo T, Matsuzaki M, Worgall TS, 
Deckelbaum RJ: n-3 fatty acids reduce arterial 
LDL-cholesterol delivery and arterial lipoprotein 
lipase levels and lipase distribution. Arterioscler 
Thromb Vasc Biol 2009-561.  
22. Simopoulos AP, Tan DX, Manchester LC, Reiter 
RJ: Purslane: a plant source of omega-3 fatty 
acids and melatonin. J Pineal Res 2005-
332. 
23. Rodriguez C, Mayo JC, Sainz RM, Antolín I, 
Herrera F, Martín V, et al: Regulation of 
antioxidant enzymes: a significant role for 
melatonin. J Pineal Res 2004-9. 
24. Hoyos M, Guerrero JM, Perez-Cano R, Olivan J, 
Fabiani F, Garcia-Pergañeda A, et al: Serum 
cholesterol and lipid peroxidation are decreased 
by melatonin in diet-induced 
hypercholesterolemic rats. J Pineal Res 2000; 
28:150-155. 
25. Liu L, Howe P, Zhou YF, Xu ZQ, Hocart C, 
Zhan R: Fatty acids and beta-carotene in 
australian purslane (Portulaca oleracea) varieties. 
J Chromatogr A 2000-213. 
26. Hongxing Z, Nancai Y, Guofu H, Jianbo S, 
Yanxia W, Hanju H, et al: Neuroprotective 
effects of purslane herb aquenous extracts 
against D-galactose induced neurotoxicity. Chem 
Biol Interact 2007; 170:145-152.. 
27. YouGuo C, ZongJi S, XiaoPing C: Evaluation of 
free radicals scavenging and immunity-
modulatory activities of Purslane 
polysaccharides. Int J Biol Macromol  45: 
448-452.  
28. Mackness B, Durrington PN, Mackness MI: The 
paraoxonase gene family and coronary heart 
disease. Curr Opin Lipidol 2002; 13:357-362. 
29. Suehiro T, Nakamura T, Inoue M, Shiinoki T, 
Ikeda Y, Kumon Y, et al: A polymorphism 
upstream from the human paraoxonase (PON1) 
gene and its association with PON1 expression. 
Atherosclerosis  150:295-298.  
30. Ferretti G, Bacchetti T, Marchionni C, Caldarelli 
L, Curatola G: Effect of glycation of high 
density lipoproteins on their physicochemical 
properties and on paraoxonase activity. Acta 
Diabetol  38: 163-169. 
31. Rantala M, Silaste ML, Tuominen A, Kaikkonen 
J, Salonen JT, Alfthan G, et al: Dietary 
modifications and gene polymorphisms alter 
serum paraoxonase activity in healthy women. J 
Nutr  132:3012-3017. 
32. Van Himbergen TM, Roest M, de Graaf J, 
Jansen EH, Hattori H, Kastelein JJ, et al: 
Indications that paraoxonase-1 contributes to 
plasma high density lipoprotein levels in familial 
hypercholesterolemia. J Lipid Res  46:445-
451. 
 
 
 
12/21/2012 
